| |
| |
|
| Insider
Information: |
Orbimed Capital Gp Vii Llc |
| Relationship: |
|
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
28,157,598 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$440,273,315 |
|
|
| Total
Shares |
28,157,598 |
|
|
| Total
Value |
$440,273,315 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
10
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 -38.0%
|
-137.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Synthorx, Inc. |
THOR |
10% Owner |
2018-12-11 |
0 |
2018-12-11 |
5,316,355 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-03 |
0 |
2022-06-24 |
415,142 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-02-28 |
0 |
2023-06-28 |
8,034,000 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2020-03-12 |
0 |
2021-07-16 |
4,199,068 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2022-07-01 |
0 |
2022-07-01 |
0 |
Premium* |
|
|
Third Harmonic Bio, Inc. |
THRD |
Director, 10% Owner |
2022-09-19 |
0 |
2022-09-19 |
5,779,071 |
Premium* |
|
|
Galecto Inc. |
GLTO |
10% Owner |
2023-04-05 |
0 |
2023-08-15 |
1,510,375 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2023-07-17 |
0 |
2023-07-17 |
650,600 |
Premium* |
|
|
Q32 Bio Inc |
QTTB |
|
|
0 |
2024-03-25 |
2,252,987 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| QTTB |
Q32 Bio Inc |
|
– • • |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,252,987 |
|
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-08-15 |
4 |
S |
$0.75 |
$617,010 |
I/I |
(822,680) |
1,510,375 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-07-31 |
4 |
S |
$3.00 |
$628,200 |
I/I |
(209,400) |
2,105,909 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-07-25 |
4 |
S |
$2.92 |
$114,464 |
I/I |
(39,200) |
2,258,987 |
0 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2023-07-17 |
4 |
B |
$3.05 |
$1,463,793 |
I/I |
479,932 |
650,600 |
2.25 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-07-13 |
4 |
S |
$2.40 |
$467,280 |
I/I |
(194,700) |
2,285,687 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
10% Owner |
– – • |
2023-06-28 |
4 |
B |
$0.84 |
$483,164 |
I/I |
575,195 |
8,034,000 |
1.5 |
% |
|
| PASG |
Passage Bio, Inc. |
10% Owner |
– – • |
2023-06-27 |
4 |
B |
$0.84 |
$518,601 |
I/I |
617,382 |
7,458,805 |
1.5 |
% |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-17 |
4 |
S |
$1.97 |
$25,785 |
I/I |
(13,089) |
2,417,787 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-14 |
4 |
S |
$1.86 |
$77,090 |
I/I |
(41,446) |
2,426,665 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-13 |
4 |
S |
$1.82 |
$25,382 |
I/I |
(13,946) |
2,454,775 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-12 |
4 |
S |
$1.81 |
$4,277 |
I/I |
(2,363) |
2,464,234 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-11 |
4 |
S |
$1.82 |
$25,382 |
I/I |
(13,946) |
2,465,837 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-10 |
4 |
S |
$1.79 |
$91,698 |
I/I |
(51,228) |
2,500,582 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-06 |
4 |
S |
$2.00 |
$19,330 |
I/I |
(9,665) |
2,510,041 |
0 |
- |
|
| GLTO |
Galecto Inc. |
10% Owner |
– – • |
2023-04-05 |
4 |
S |
$2.18 |
$202,664 |
I/I |
(92,965) |
2,516,599 |
0 |
- |
|
| THRD |
Third Harmonic Bio, Inc. |
Director |
– • • |
2022-09-19 |
4 |
A |
$0.00 |
$0 |
I/I |
5,479,071 |
5,479,071 |
0 |
- |
|
| THRD |
Third Harmonic Bio, Inc. |
Director |
– • • |
2022-09-19 |
4 |
B |
$17.00 |
$5,100,000 |
I/I |
300,000 |
5,779,071 |
2.25 |
% |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • • |
2022-07-01 |
4 |
D |
$55.00 |
$108,062,350 |
I/I |
(1,964,770) |
0 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
– – • |
2022-06-24 |
4 |
S |
$21.31 |
$7,287,402 |
I/I |
(341,971) |
415,142 |
0 |
% |
|
| PASG |
Passage Bio, Inc. |
10% Owner |
– – • |
2022-05-04 |
4 |
B |
$1.94 |
$588,790 |
I/I |
303,500 |
6,841,423 |
1.5 |
% |
|
| PASG |
Passage Bio, Inc. |
10% Owner |
– – • |
2022-05-03 |
4 |
B |
$1.93 |
$427,495 |
I/I |
221,500 |
6,537,923 |
1.5 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
– – • |
2022-04-08 |
4 |
S |
$20.71 |
$4,142,000 |
I/I |
(200,000) |
451,086 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
– – • |
2022-04-07 |
4 |
S |
$20.66 |
$7,127,617 |
I/I |
(344,996) |
553,886 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
– – • |
2022-04-06 |
4 |
S |
$20.69 |
$6,893,991 |
I/I |
(333,204) |
731,082 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
